EP Patent

EP3943069A1 — Ophthalmic formulations of cetirizine and methods of use

Assigned to Nicox Ophthalmics Inc · Expires 2022-01-26 · 4y expired

What this patent protects

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treatin…

USPTO Abstract

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Drugs covered by this patent

Patent Metadata

Patent number
EP3943069A1
Jurisdiction
EP
Classification
Expires
2022-01-26
Drug substance claim
No
Drug product claim
No
Assignee
Nicox Ophthalmics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.